Genovis AB (publ) to publish Q1 2015 report ahead of schedule

The Board of Directors of Genovis AB (publ) has decided to publish Q1 2015
report ahead of schedule.
The Interim Report for January-March, which was to be announced on May 11, 2015,
will be published ahead of schedule. The new publication date for the report is
April 15, 2015.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
0046 (0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00